{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:05:35Z","timestamp":1781755535579,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although multiple myeloma (MM) is still considered as an incurable disease by current standards, the development of several combination therapies, and immunotherapy approaches has raised the hope towards transforming MM into an indolent, chronic disease, and possibly achieving a cure. We tried to shed light on the expression of PD1 and different Microparticles (MPs) in MM and their interplay as a mechanism of resistance to standardized treatments, in addition, find their associations with prognostic factors of symptomatic MM. Thirty patients with newly diagnosed and chemotherapy na\u00efve active MM, along with 19 healthy participants of comparable age and sex were recruited, after diagnosis of MM; blood samples were collected from both patients and controls for flow cytometric detection of CD4+, CD8+, CD4+PD1+, and CD8+PD1+T cells, total MPs, CD138+ MPs, and platelet MPs. MM patients had statistically significant higher levels of TMPs, CD138+ MPs compared to their controls, while PMPs exhibited no significant difference between both groups. Statistically significant higher percentages of CD8+, PD1CD8+, PD1CD4+T cells were detected in patients compared to controls, while the latter group had a significantly higher percentage of CD4+T cells than MM patients, patients who did not achieve complete response, had significantly higher percentages of PMPs, CD138+MPs, PD1+CD8+, PD1+CD4+, and CD8+T cells (cutoff values\u2009=\u200961, 10.6, 13.5, 11.3 and 20.1 respectively), (\n                    <jats:italic>p<\/jats:italic>\n                    -values\u2009=\u20090.002, 0.003, 0.017, 0.001 and 0.008 respectively). Microparticles and PD1 expressions were associated with proliferative potential and resistance to Bortezomib-based treatments, our results suggested that they played a crucial role in myeloma progression.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-96975-4","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:22:07Z","timestamp":1630657327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Microparticles and PD1 interplay added a prognostic impact in treatment outcomes of patients with multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"given":"Asmaa M.","family":"Zahran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab Albadry M.","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Rayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"10","key":"96975_CR1","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/cncr.31243","volume":"124","author":"M K\u00f6hler","year":"2018","unstructured":"K\u00f6hler, M. et al. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer 124(10), 2075\u20132085 (2018).","journal-title":"Cancer"},{"issue":"3","key":"96975_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1586\/17474086.2015.1029449","volume":"8","author":"SV Glavey","year":"2015","unstructured":"Glavey, S. V. & Ghobrial, I. M. American Society of Hematology Annual Meeting 2014: Highlights in multiple myeloma. Expert Rev. Hematol. 8(3), 273\u2013275 (2015).","journal-title":"Expert Rev. Hematol."},{"issue":"8","key":"96975_CR3","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau, H. et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 109(8), 3489\u20133495 (2007).","journal-title":"Blood"},{"issue":"3","key":"96975_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/leu.2009.273","volume":"24","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau, H. et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 24(3), 623\u2013628 (2010).","journal-title":"Leukemia"},{"issue":"4","key":"96975_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hon.2648","volume":"37","author":"Z-Y Liu","year":"2019","unstructured":"Liu, Z.-Y. et al. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring. Hematol. Oncol. 37(4), 401\u2013408 (2019).","journal-title":"Hematol. Oncol."},{"issue":"4","key":"96975_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/fon.13.230","volume":"10","author":"R Jaiswal","year":"2014","unstructured":"Jaiswal, R., Raymond Grau, G. E. & Bebawy, M. Cellular communication via microparticles: Role in transfer of multidrug resistance in cancer. Future Oncol. 10(4), 655\u2013669 (2014).","journal-title":"Future Oncol."},{"key":"96975_CR7","first-page":"220","volume":"4","author":"J Gong","year":"2014","unstructured":"Gong, J., Luk, F., Jaiswal, R. & Bebawy, M. Microparticles mediate the intercellular regulation of microRNA-503 and proline-rich tyrosine kinase 2 to alter the migration and invasion capacity of breast cancer cells. Front. Oncol. 4, 220 (2014).","journal-title":"Front. Oncol."},{"key":"96975_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2013.07.009","volume":"76","author":"JF Lu","year":"2013","unstructured":"Lu, J. F. et al. Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol. Res. 76, 77\u201383 (2013).","journal-title":"Pharmacol. Res."},{"issue":"3","key":"96975_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron, A. C. et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93(3), 431\u2013438 (2008).","journal-title":"Haematologica"},{"issue":"62","key":"96975_CR10","doi-asserted-by":"publisher","first-page":"32024","DOI":"10.18632\/oncotarget.25882","volume":"9","author":"A-M Sponaas","year":"2018","unstructured":"Sponaas, A.-M. et al. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget 9(62), 32024 (2018).","journal-title":"Oncotarget"},{"issue":"1","key":"96975_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung, D. J. et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy. Cancer Immunol. Res. 4(1), 61\u201371 (2016).","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"96975_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2326-6066.CIR-15-0296","volume":"4","author":"M Ishibashi","year":"2016","unstructured":"Ishibashi, M. et al. Myeloma drug resistance induced by binding of myeloma B7\u2013H1 (PD-L1) to PD-1. Cancer Immunol. Res. 4(9), 779\u2013788 (2016).","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"96975_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","volume":"229","author":"JL Riley","year":"2009","unstructured":"Riley, J. L. PD-1 signaling in primary T cells. Immunol. Rev. 229(1), 114\u2013125 (2009).","journal-title":"Immunol. Rev."},{"issue":"10","key":"96975_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm.2232","volume":"16","author":"M Quigley","year":"2010","unstructured":"Quigley, M. et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 16(10), 1147\u20131151 (2010).","journal-title":"Nat. Med."},{"issue":"11","key":"96975_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3324\/haematol.2009.008938","volume":"94","author":"JVB Eduard","year":"2009","unstructured":"Eduard, J. V. B. et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 94(11), 1513\u20131519 (2009).","journal-title":"Haematologica"},{"key":"96975_CR16","doi-asserted-by":"publisher","first-page":"437971","DOI":"10.1155\/2014\/437971","volume":"2014","author":"AS Ibrahim","year":"2014","unstructured":"Ibrahim, A. S., Khaled, H. M., Mikhail, N. N. H., Baraka, H. & Kamel, H. Cancer incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J. Cancer Epidemiol. 2014, 437971 (2014).","journal-title":"J. Cancer Epidemiol."},{"issue":"12","key":"96975_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15(12), e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"issue":"1","key":"96975_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-2141.2002.03231.x","volume":"116","author":"G Tricot","year":"2002","unstructured":"Tricot, G. et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br. J. Haematol. 116(1), 211\u2013217 (2002).","journal-title":"Br. J. Haematol."},{"issue":"3","key":"96975_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi, P. et al. Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 8(3), 26 (2018).","journal-title":"Blood Cancer J."},{"issue":"1","key":"96975_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1586\/17474086.2014.878226","volume":"7","author":"J Rosenblatt","year":"2014","unstructured":"Rosenblatt, J., Bar-Natan, M., Munshi, N. C. & Avigan, D. E. Immunotherapy for multiple myeloma. Expert Rev. Hematol. 7(1), 91\u201396 (2014).","journal-title":"Expert Rev. Hematol."},{"issue":"7","key":"96975_CR21","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1038\/bcj.2015.49","volume":"5","author":"T Dosani","year":"2015","unstructured":"Dosani, T., Carlsten, M., Maric, I. & Landgren, O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 5(7), e321 (2015).","journal-title":"Blood Cancer J."},{"issue":"5","key":"96975_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/leu.2013.310","volume":"28","author":"D Atanackovic","year":"2014","unstructured":"Atanackovic, D., Luetkens, T. & Kr\u00f6ger, N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 28(5), 993\u20131000 (2014).","journal-title":"Leukemia"},{"key":"96975_CR23","doi-asserted-by":"crossref","unstructured":"Ribas, A. et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). Am. Soc. Clin. Oncol. 2014.","DOI":"10.1200\/jco.2014.32.18_suppl.lba9000"},{"issue":"26","key":"96975_CR24","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"96975_CR25","doi-asserted-by":"publisher","first-page":"20846","DOI":"10.1038\/s41598-020-77941-y","volume":"10","author":"EV Batorov","year":"2020","unstructured":"Batorov, E. V. et al. Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients. Sci. Rep. 10(1), 20846 (2020).","journal-title":"Sci. Rep."},{"issue":"62","key":"96975_CR26","doi-asserted-by":"publisher","first-page":"32024","DOI":"10.18632\/oncotarget.25882","volume":"9","author":"AM Sponaas","year":"2018","unstructured":"Sponaas, A. M. et al. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget 9(62), 32024\u201332035 (2018).","journal-title":"Oncotarget"},{"issue":"9","key":"96975_CR27","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/leu.2009.76","volume":"23","author":"M Bebawy","year":"2009","unstructured":"Bebawy, M. et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 23(9), 1643\u20131649 (2009).","journal-title":"Leukemia"},{"issue":"12","key":"96975_CR28","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/rheumatology\/ken373","volume":"47","author":"U Erdbruegger","year":"2008","unstructured":"Erdbruegger, U. et al. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology 47(12), 1820\u20131825 (2008).","journal-title":"Rheumatology"},{"issue":"8","key":"96975_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1055\/s-0031-1297372","volume":"37","author":"A Coppola","year":"2011","unstructured":"Coppola, A., Tufano, A., Di Capua, M. & Franchini, M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin. Thromb. Hemost. 37(8), 929\u2013945 (2011).","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"96975_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tmrv.2005.08.001","volume":"20","author":"J Simak","year":"2006","unstructured":"Simak, J. & Gelderman, M. P. Cell membrane microparticles in blood and blood products: Potentially pathogenic agents and diagnostic markers. Transfus. Med. Rev. 20(1), 1\u201326 (2006).","journal-title":"Transfus. Med. Rev."},{"issue":"1","key":"96975_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neo.2015.11.011","volume":"18","author":"SR Krishnan","year":"2016","unstructured":"Krishnan, S. R. et al. Isolation of human CD138(+) microparticles from the plasma of patients with multiple myeloma. Neoplasia 18(1), 25\u201332 (2016).","journal-title":"Neoplasia"},{"key":"96975_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.micron.2013.08.010","volume":"54\u201355","author":"T Benameur","year":"2013","unstructured":"Benameur, T. et al. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron 54\u201355, 75\u201381 (2013).","journal-title":"Micron"},{"issue":"Suppl 7","key":"96975_CR33","doi-asserted-by":"publisher","first-page":"vii143","DOI":"10.1093\/annonc\/mdq370","volume":"21","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. A. & Terpos, E. Multiple myeloma. Ann. Oncol. 21(Suppl 7), vii143\u2013vii150 (2010).","journal-title":"Ann. Oncol."},{"issue":"9","key":"96975_CR34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/sj.leu.2404296","volume":"20","author":"J Ratajczak","year":"2006","unstructured":"Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A. & Ratajczak, M. Z. Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication. Leukemia 20(9), 1487\u20131495 (2006).","journal-title":"Leukemia"},{"issue":"9","key":"96975_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCRESAHA.110.226456","volume":"107","author":"SF Mause","year":"2010","unstructured":"Mause, S. F. & Weber, C. Microparticles: Protagonists of a novel communication network for intercellular information exchange. Circ. Res. 107(9), 1047\u20131057 (2010).","journal-title":"Circ. Res."},{"issue":"1\u20132","key":"96975_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12307-014-0144-8","volume":"7","author":"T Voloshin","year":"2014","unstructured":"Voloshin, T., Fremder, E. & Shaked, Y. J. C. M. Small but mighty: Microparticles as mediators of tumor progression. Cancer Microenviron. 7(1\u20132), 11\u201321 (2014).","journal-title":"Cancer Microenviron."},{"issue":"2","key":"96975_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41556-018-0256-3","volume":"21","author":"I Keklikoglou","year":"2019","unstructured":"Keklikoglou, I. et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat. Cell Biol. 21(2), 190\u2013202 (2019).","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"96975_CR38","doi-asserted-by":"publisher","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","volume":"4","author":"FL Ricklefs","year":"2018","unstructured":"Ricklefs, F. L. et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4(3), eaar2766 (2018).","journal-title":"Sci. Adv."},{"issue":"7718","key":"96975_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718), 382\u2013386 (2018).","journal-title":"Nature"},{"issue":"1","key":"96975_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41388-019-0971-7","volume":"39","author":"M Timaner","year":"2020","unstructured":"Timaner, M. et al. Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. Oncogene 39(1), 187\u2013203 (2020).","journal-title":"Oncogene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96975-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96975-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96975-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:15:41Z","timestamp":1670062541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96975-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["96975"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-96975-4","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/7EEFVX","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17681"}}